Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Lehmacher

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
The New England Journal of Medicine|January 29, 2010
Benefit assessment in GermanyJoerg Hasford, Walter Lehmacher
Medizinische Monatsschrift Fur Pharmazeuten|September 26, 2009
[Postmarketing surveillance studies in community pharmacies]Karen Nieber, Walter Lehmacher
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|December 14, 2011
[The relevance of head-to-head trials to patient-centred clinical research]Walter Lehmacher, Stephanie Wolff
Current Opinion in Allergy and Clinical Immunology|May 21, 2009
The problem of placebo-controlled trials allowing rescue medication: how to assess efficacy in rhinosinusitis and allergic rhinoconjunctivitis when both groups receive active rescue treatmentJulia Vent, Walter Lehmacher
Multidisciplinary Respiratory Medicine|July 21, 2023
Effects of EPs 7630 on the duration of inability to work in acute bronchitis - a meta-analysisHeinrich Matthys, Petra Funk, Andrea Zimmermann, et al.
International Archives of Allergy and Immunology|March 2, 2006
Comparison of the biological activity of the most common sublingual allergen solutions made by two European manufacturersRalph Mösges, Norbert Pasch, Ulf Schlierenkämper, et al.
Frontiers in Neurology|November 9, 2023
Correlation of effectiveness and tolerability assessments from a pharmacy-based observational study investigating the fixed-dose combination of 400 mg ibuprofen plus 100 mg caffeine for the treatment of acute headacheCharly Gaul, Stefanie Förderreuther, Walter Lehmacher, et al.
Asian Pacific Journal of Allergy and Immunology|March 18, 2010
Assessment of the antiobstructive effect of fexofenadine on nasal allergy challenge in patients with seasonal allergic rhinitisRalph Mösges, Walter Lehmacher, Norbert Pasch, et al.
European Journal of Neurology|September 14, 2021
Aspirin, paracetamol (acetaminophen) and caffeine for the treatment of acute migraine attacks: A systemic review and meta-analysis of randomized placebo-controlled trialsHans Christoph Diener, Charly Gaul, Walter Lehmacher, et al.
Current Medical Research and Opinion|November 10, 2017
EPs 7630 is effective and safe in children under 6 years with acute respiratory tract infections: clinical studies revisitedWolfgang Kamin, Petra Funk, Georg Seifert, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
The New England Journal of Medicine|January 29, 2010
Benefit assessment in GermanyJoerg Hasford, Walter Lehmacher
Medizinische Monatsschrift Fur Pharmazeuten|September 26, 2009
[Postmarketing surveillance studies in community pharmacies]Karen Nieber, Walter Lehmacher
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|December 14, 2011
[The relevance of head-to-head trials to patient-centred clinical research]Walter Lehmacher, Stephanie Wolff
Current Opinion in Allergy and Clinical Immunology|May 21, 2009
The problem of placebo-controlled trials allowing rescue medication: how to assess efficacy in rhinosinusitis and allergic rhinoconjunctivitis when both groups receive active rescue treatmentJulia Vent, Walter Lehmacher
Multidisciplinary Respiratory Medicine|July 21, 2023
Effects of EPs 7630 on the duration of inability to work in acute bronchitis - a meta-analysisHeinrich Matthys, Petra Funk, Andrea Zimmermann, et al.
International Archives of Allergy and Immunology|March 2, 2006
Comparison of the biological activity of the most common sublingual allergen solutions made by two European manufacturersRalph Mösges, Norbert Pasch, Ulf Schlierenkämper, et al.
Frontiers in Neurology|November 9, 2023
Correlation of effectiveness and tolerability assessments from a pharmacy-based observational study investigating the fixed-dose combination of 400 mg ibuprofen plus 100 mg caffeine for the treatment of acute headacheCharly Gaul, Stefanie Förderreuther, Walter Lehmacher, et al.
Asian Pacific Journal of Allergy and Immunology|March 18, 2010
Assessment of the antiobstructive effect of fexofenadine on nasal allergy challenge in patients with seasonal allergic rhinitisRalph Mösges, Walter Lehmacher, Norbert Pasch, et al.
European Journal of Neurology|September 14, 2021
Aspirin, paracetamol (acetaminophen) and caffeine for the treatment of acute migraine attacks: A systemic review and meta-analysis of randomized placebo-controlled trialsHans Christoph Diener, Charly Gaul, Walter Lehmacher, et al.
Current Medical Research and Opinion|November 10, 2017
EPs 7630 is effective and safe in children under 6 years with acute respiratory tract infections: clinical studies revisitedWolfgang Kamin, Petra Funk, Georg Seifert, et al.
Pageof 7